We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Early Blood Testing for Viral Measurement During Initial Diagnosis Can Predict Long COVID

By HospiMedica International staff writers
Posted on 24 Jan 2022
Print article
Illustration
Illustration

Researchers have identified several factors that can be measured using blood tests at the initial point of COVID-19 diagnosis that anticipate if a patient is likely to develop long COVID.

These “PASC factors” identified by researchers at the Institute for Systems Biology (ISB; Seattle, WA, USA) are the presence of certain autoantibodies, pre-existing Type 2 diabetes, SARS-CoV-2 RNA levels in the blood, and Epstein-Barr virus DNA levels in blood. Additionally, the researchers found that mild cases of COVID-19, not just severe cases, are associated with long COVID. They have also suggested administering antivirals very early in the disease course to potentially prevent some Post Acute Sequelae of COVID-19 (PASC) symptoms.

A significant portion of people who contract the SARS-CoV-2 virus – some estimates suggest more than 40% – suffer chronic effects known as PASC, commonly referred to as long COVID. PASC symptoms include fatigue, brain fog, the loss of taste and smell, shortness of breath, and more. For their study, the researchers collected blood and swab samples from 309 COVID-19 patients at different time points to perform comprehensive phenotyping which was integrated with clinical data and patient-reported symptoms to carry out a deep multi-omic, longitudinal investigation. A key finding from the study deals with viral load, which can be measured near diagnosis to predict long COVID symptoms.

In addition, researchers found the Epstein-Barr virus (EBV) – a virus that infects 90 percent of the human population and is normally inactive in the body after infection – is reactivated early on after SARS-CoV-2 infection, which is significantly associated with future long COVID symptoms. The team also found that PASC is anticipated by autoantibodies (which associate with autoimmune diseases like lupus) at diagnosis, and that as autoantibodies increase, protective SARS-CoV-2 antibodies decrease. This suggests a relationship between long COVID, autoantibodies and patients at elevated risk of re-infections.

“Identifying these PASC factors is a major step forward for not only understanding long COVID and potentially treating it, but also which patients are at highest risk for the development of chronic conditions,” said ISB President, Dr. Jim Heath. “These findings are also helping us frame our thinking around other chronic conditions, such as post-acute Lyme syndrome, for example.”

“Long COVID is causing significant morbidity in survivors of COVID-19, yet the pathobiology is poorly understood,” said Dr. Jason Goldman, an infectious disease expert at Swedish. “Our study pairs clinical data and patient-reported outcomes with deep multi-omic analyses to unravel important biological associations that occur in patients with PASC. Certain findings such as the low cortisol state in patients with long COVID have potential to translate rapidly to the clinic. Our results form an important foundation for the development of therapeutics to treat long COVID.”

Related Links:
ISB

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Examination Data Management Software
DiVAS 2.8

Print article

Channels

Critical Care

view channel
Image: The stretchable microneedle electrode arrays (Photo courtesy of Zhao Research Group)

Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment

The field of personalized medicine is transforming rapidly, with advancements like wearable devices and home testing kits making it increasingly easy to monitor a wide range of health metrics, from heart... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more